CMC plays a pivotal role in the success of partnerships and licensing deals. This session dives into how recent FDA actions are shaping due diligence, strategies to streamline cross-disciplinary communication, and best practices for handling early-stage products with limited CMC data.
- The latest FDA actions impacting CMC due diligence.
- Tips for effective collaboration across technical and business teams.
- How to evaluate early-stage products when data is incomplete.
